Sodium-glucose cotransporter type 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies

被引：0
|
作者：
Tomasoni, Daniela
Stretti, Lorenzo
Adamo, Marianna
Metra, Marco
机构：
[1] Univ Brescia, Dipartimento Cardiotorac, UO Cardiol, ASST Spedali Civili Brescia, Brescia, Italy
[2] Univ Brescia, Dipartimento Specialita Med Chirurg Sci Radiol &, Brescia, Italy
来源：
GIORNALE ITALIANO DI CARDIOLOGIA | 2023年 / 24卷 / 04期
关键词：
CARDIOVASCULAR OUTCOMES; EMPAGLIFLOZIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：251 / 254
页数：4
相关论文
共 50 条
  • [41] Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
    Feng, Bin
    Yu, Peiran
    Yu, Hao
    Qian, Buyun
    Li, Yuan
    Sun, Kangyun
    Shi, Bimin
    Zhang, Nannan
    Xu, Guidong
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [42] Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
    Lou, Yake
    Yang, Qi
    Zhang, Weicong
    Yu, Ying
    Huang, Jing
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (11)
  • [43] Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis
    Lan, Xiaohua
    Zhu, Huijing
    Cao, Yanjie
    Hu, Yue
    Fan, Xingman
    Zhang, Kaijie
    Wu, Mengdi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [44] Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
    Packer, Milton
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Schnaidt, Sven
    Zeller, Cordula
    Schnee, Janet M.
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (16) : 1284 - 1294
  • [45] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    Tiago Tribolet de Abreu
    Heart Failure Reviews, 2022, 27 : 2077 - 2082
  • [46] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    de Abreu, Tiago Tribolet
    HEART FAILURE REVIEWS, 2022, 27 (06) : 2077 - 2082
  • [47] Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
    Butler, Javed
    Siddiqi, Tariq Jamal
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Zannad, Faiez
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) : 245 - 248
  • [48] Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
    Cavka, Luka
    Bencak Ferko, Urska
    Pitz, Natasa
    Trpkovski, Zoranco
    Lainscak, Mitja
    ESC HEART FAILURE, 2021, 8 (04): : 2631 - 2636
  • [49] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
    Yousef, Zaheer
    HEART, 2022, 108 : A79 - A80
  • [50] Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial
    Green, Jennifer
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S25 - S25
12345